Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach

Katherine Kay, Keith Dolcy, Robert Bies, Dhaval K. Shah

Research output: Contribution to journalArticle

Abstract

Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. The PFS plot showing fastest tumor growth was deemed to best represent the inherent growth kinetics of the solid tumor, and selected for further analysis. The exponential tumor growth rates were extracted from each PFS plot, along with associated variabilities, which ultimately allowed for the estimation of solid tumor doubling times. The mean simulated doubling times for pancreatic cancer, melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, hormone receptor positive (HR+) breast cancer, human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, gastric cancer, glioblastoma multiforme, colorectal cancer, and prostate cancer were 5.06, 3.78, 3.06, 2.67, 2.38, 2.40, 4.31, 4.12, and 3.84 months, respectively. For all cancers, clinically reported doubling times were within the estimated ranges. For all cancers, except HCC, the growth rates were best characterized by a log-normal distribution. For HCC, the gamma distribution best described the data. The statistical approach presented here provides a qualified method for extracting tumor growth rates and doubling times from PFS plots. It also allows estimation of the distributional characteristics for tumor growth rates and doubling times in a given patient population.

Original languageEnglish (US)
Article number27
JournalAAPS Journal
Volume21
Issue number2
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Disease-Free Survival
Neoplasms
Growth
Hepatocellular Carcinoma
Stomach Neoplasms
Prostatic Neoplasms
Triple Negative Breast Neoplasms
Breast Neoplasms
Normal Distribution
Glioblastoma
Pancreatic Neoplasms
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
Melanoma
Hormones

Keywords

  • PK/PD modeling and simulation
  • preclinical-to-clinical translation
  • progression-free survival
  • solid tumor doubling time
  • tumor growth rate

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach. / Kay, Katherine; Dolcy, Keith; Bies, Robert; Shah, Dhaval K.

In: AAPS Journal, Vol. 21, No. 2, 27, 01.03.2019.

Research output: Contribution to journalArticle

@article{83b48d4bc95c48958f59522a667b1b9d,
title = "Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach",
abstract = "Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. The PFS plot showing fastest tumor growth was deemed to best represent the inherent growth kinetics of the solid tumor, and selected for further analysis. The exponential tumor growth rates were extracted from each PFS plot, along with associated variabilities, which ultimately allowed for the estimation of solid tumor doubling times. The mean simulated doubling times for pancreatic cancer, melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, hormone receptor positive (HR+) breast cancer, human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, gastric cancer, glioblastoma multiforme, colorectal cancer, and prostate cancer were 5.06, 3.78, 3.06, 2.67, 2.38, 2.40, 4.31, 4.12, and 3.84 months, respectively. For all cancers, clinically reported doubling times were within the estimated ranges. For all cancers, except HCC, the growth rates were best characterized by a log-normal distribution. For HCC, the gamma distribution best described the data. The statistical approach presented here provides a qualified method for extracting tumor growth rates and doubling times from PFS plots. It also allows estimation of the distributional characteristics for tumor growth rates and doubling times in a given patient population.",
keywords = "PK/PD modeling and simulation, preclinical-to-clinical translation, progression-free survival, solid tumor doubling time, tumor growth rate",
author = "Katherine Kay and Keith Dolcy and Robert Bies and Shah, {Dhaval K.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1208/s12248-019-0302-5",
language = "English (US)",
volume = "21",
journal = "AAPS Journal",
issn = "1550-7416",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach

AU - Kay, Katherine

AU - Dolcy, Keith

AU - Bies, Robert

AU - Shah, Dhaval K.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. The PFS plot showing fastest tumor growth was deemed to best represent the inherent growth kinetics of the solid tumor, and selected for further analysis. The exponential tumor growth rates were extracted from each PFS plot, along with associated variabilities, which ultimately allowed for the estimation of solid tumor doubling times. The mean simulated doubling times for pancreatic cancer, melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, hormone receptor positive (HR+) breast cancer, human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, gastric cancer, glioblastoma multiforme, colorectal cancer, and prostate cancer were 5.06, 3.78, 3.06, 2.67, 2.38, 2.40, 4.31, 4.12, and 3.84 months, respectively. For all cancers, clinically reported doubling times were within the estimated ranges. For all cancers, except HCC, the growth rates were best characterized by a log-normal distribution. For HCC, the gamma distribution best described the data. The statistical approach presented here provides a qualified method for extracting tumor growth rates and doubling times from PFS plots. It also allows estimation of the distributional characteristics for tumor growth rates and doubling times in a given patient population.

AB - Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. The PFS plot showing fastest tumor growth was deemed to best represent the inherent growth kinetics of the solid tumor, and selected for further analysis. The exponential tumor growth rates were extracted from each PFS plot, along with associated variabilities, which ultimately allowed for the estimation of solid tumor doubling times. The mean simulated doubling times for pancreatic cancer, melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, hormone receptor positive (HR+) breast cancer, human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, gastric cancer, glioblastoma multiforme, colorectal cancer, and prostate cancer were 5.06, 3.78, 3.06, 2.67, 2.38, 2.40, 4.31, 4.12, and 3.84 months, respectively. For all cancers, clinically reported doubling times were within the estimated ranges. For all cancers, except HCC, the growth rates were best characterized by a log-normal distribution. For HCC, the gamma distribution best described the data. The statistical approach presented here provides a qualified method for extracting tumor growth rates and doubling times from PFS plots. It also allows estimation of the distributional characteristics for tumor growth rates and doubling times in a given patient population.

KW - PK/PD modeling and simulation

KW - preclinical-to-clinical translation

KW - progression-free survival

KW - solid tumor doubling time

KW - tumor growth rate

UR - http://www.scopus.com/inward/record.url?scp=85061262966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061262966&partnerID=8YFLogxK

U2 - 10.1208/s12248-019-0302-5

DO - 10.1208/s12248-019-0302-5

M3 - Article

C2 - 30737615

AN - SCOPUS:85061262966

VL - 21

JO - AAPS Journal

JF - AAPS Journal

SN - 1550-7416

IS - 2

M1 - 27

ER -